In patients with MASLD and MASH, hepatic expression of IRS-1 was maintained, whereas expression of IRS-2 was decreased and correlated negatively with expression of PCK1 and G6PC [68]. This evidence concerns the gene PCK1 and metabolic dysfunction-associated steatotic liver disease.